Methods for treating patients with hematologic malignancies

The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting cell-proliferation which is activated by wild-type or mutated Fms-like tyrosinekinase-3 receptor (FLT3). The present disclosure further relates to a method of inhibiting or reducing abnormal (e.g., overexpressed) wild-type or mutated BTK activity or expression in a subject in need thereof. 本公开包括一种用于施用2,3-二氢-异吲哚-1-酮化合物或其药学上可接受的盐、酯、溶剂合物和/或前药以治疗血液癌症诸如急性骨髓性白血病(AML)的方法。本公开进一步涉及降低或抑制由野生型或突变Fms样酪氨酸激酶-3受体(FLT3)活化的细胞增殖。本公开进一步涉及一种抑制或降低有需要的受试者中的异常(例如过度表达)野生型或突变BTK活性或表达的方法。